Drug disinvestment frameworks: Components, challenges, and solutions

International Journal of Technology Assessment in Health Care

Volumn 33, Issue 2, 2017, Pages 261-269

  Maloney, Mary Alison ^a   Schwartz, Lisa ^b   O'Reilly, Daria ^c   Levine, Mitchel ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Budgets; Disinvestment; Reassessment; Technology assessment

Indexed keywords

BUDGET CONTROL; OBSOLESCENCE;

BUDGETS; DISINVESTMENT; HEALTH TECHNOLOGY ASSESSMENTS; INTERNATIONAL NETWORKS; QUALITATIVE DECISION MAKING; REASSESSMENT; SYSTEMATIC LITERATURE REVIEW; TECHNOLOGY ASSESSMENTS;

INVESTMENTS;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG FORMULARY; HUMAN; INVESTMENT; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL TECHNOLOGY; REIMBURSEMENT; RESOURCE ALLOCATION; SAFETY; SOCIAL ASPECT; SYSTEMATIC REVIEW; DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY;

DECISION MAKING; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85023778793     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462317000277     Document Type: Article

References (45)

1. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? BMJ. 2011;343:261.
2. MacKean G, Noseworthy T, Elshaug AG, et al. Health technology reassessment: The art of the possible. Int J Technol Assess Health Care. 2013;29:418-269.
3. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-269. W64.
4. Elshaug AG, Hiller J, Tunis SR, Moss J. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy. 2007;4:23.
5. Gnjidic D, Elshaug AG. De-adoption and its 43 related terms: Harmonizing low-value care terminology. BMC Med. 2015;13:273.
6. Ibargoyen-Roteta N, Gutierrez-Ibarluzea I, Asua J. Guiding the process of health technology disinvestment. Health Policy. 2010;98:218-226.
7. Parkinson B, Sermet C, Clement F, et al. Disinvestment and valuebased purchasing strategies for pharmaceuticals: An international review. Pharmacoeconomics. 2015;33:905-924.
8. Wilson MG, EllenME, Lavis JN, et al. Processes, contexts, and rationale for disinvestment: A protocol for a critical interpretive synthesis. Syst Rev. 2014;3:143.
9. Elshaug AG, Moss J, Littlejohns P, Karnon J, Merlin T, Hiller J. Identifying existing health care services that do not provide value for money. Med J Aust. 2009;190:269-373.
10. Gerdvilaite J, Nachtnebel A. Disinvestment: Overview of disinvestment experiences and challenges in selected countries. 2011. http://eprints.hta.lbg.ac.at/926/# (accessed January 30, 2016).
11. Healthcare Improvement Scotland. Technologies scoping report. 2013. http://www.healthcareimprovementscotland.org/our-work/technologies-and-medicines/earlier-scoping-reports/technologies-scoping-report-16.aspx (accessed January 31, 2016).
12. Alberta Health Services. Reassessment Program. 2016. http://www. albertahealthservices.ca/info/Page4144.aspx (accessed January 30, 2016).
13. Health Policy Advisory Committee on Technology. Disinvestment in Australia and New Zealand. Australia: Queensland Health; 2013.
14. Elshaug AG, Hiller J, Moss J. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices. Int J Technol Assess Health Care. 2008;24:1-9.
15. Morland B.Methods of no value must be abandoned. Tidsskr Nor Laegeforen. 2010;130:1256-1257.
16. Ruano Ravina A, Velasco Gonzalez M, Varela Lema L, et al. Identification, prioritisation and assessment of obsolete health technologies. A methodological guideline. Santiago de ComPostela: Galician Agency for Health Technology Assessment (AVALIA-T); 2007.
17. Joshi N, Stahlnisch F, Noseworthy T. Reassessment of heath technologies: Obsolescence and waste. 2009. http://www.cadth.ca/reassessmenthealth-technologies-obsolescence-and-waste (accessed February 6, 2016).
18. Albert Health Services. Health Technology Assessment & Innovation Department Annual Report (April 1, 2010-March 31, 2011). 2011. http://www.albertahealthservices.ca/assets/Infofor/Researchers/if-reshtai-annual-report.pdf (accessed January 30, 2016).
19. Garner S, Docherty M, Somner J, et al. Reducing ineffective practice: Challenges in identifying low-value health care using Cochrane systematic reviews. J Health Serv Res Policy. 2013;18:6-12.
20. Hughes D, Ferner R. New drugs for old: Disinvestment and NICE. BMJ. 2010;340:c572.
21. Haas M, Hall J, Viney R, Gallego G. Breaking up is hard to do: Why disinvestment in medical technology is harder than investment. Aust Health Rev. 2012;36:148-152.
22. Health Quality Ontario. Appropriateness initiative. 2014. http://www.hqontario.ca/Evidence/Evidence-Process/Appropriateness-Initiative (accessed January 30, 2016).
23. Garcia-Armesto S, Campillo-Artero C, Bernal-Delgado E. Disinvestment in the age of cost-cutting sound and fury. Tools for the Spanish National Health system. Health Policy. 2013;110:180-185.
24. Pearson S, Littlejohns P. Reallocating resources: How should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the national health service? J Health Serv Res Policy. 2007;12:160-165.
25. Scottish Health Technologies Group. Scottish health technologies group development day 2013. 2013. http://www.healthcareimprovementscotland.org/our-work/technologies-and-medicines/shtg/about-the-group/shtg-development-day-2013.aspx (accessed January 31, 2016).
26. Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: The challenge of "disinvestment". Int J Technol Assess Health Care. 2012;28:203-210.
27. Paprica A, Culyer A, Elshaug A, Peffer J, Sandoval G. From talk to action: Policy stakeholders, appropriateness, and selective disinvestment. Int J Technol Assess Health Care. 2015;31:236-240.
28. Ibargoyen-Roteta N, Gutierrez-Ibarluzea I, Asua J, Benguria-Arrate G, Galnares-Cordero L. Scanning the horizon of obsolete technologies: Possible sources for their identification. Int J Technol Assess Health Care. 2009;25:249-254.
29. Polisena J, Clifford T, Elshaug AG, Mitton C, Russell E, Skidmore B. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: A systematic review. Int J Technol Assess Health Care. 2013;29:174-184.
30. Goodman C. HTA 101: Introduction to Health Technology Assessment. http://www.nlm.nih.gov/nichsr/hta101.pdf (accessed December 19, 2015).
31. Noseworthy T, Clement F. Health technology reassessment: Scope, methodology, & language. Int J Technol Assess Health Care. 2012;28:201-202.
32. Elshaug A, Watt A, Moss J, Hiller J. Policy perspectives on the obsolescence of health technologies in Canada. 2009. http://www. cadth.ca/collaboration-and-outreach/advisory-bodies/policy-forum/discussion-papers/policy-perspectives-obsolescence-health (accessed February 6, 2016).
33. European Medicines Agency. Benefit-risk methodology project. Work package 4 report: Benefit-risk tools and processes. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/03/WC500123819.pdf (accessed October 12, 2016).
34. US Food and Drug Administration. PDUFA re-authorisation performance goals and procedures fiscal years 2013 through 2017. 2012. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf (accessed October 14, 2016).
35. Haines T, O'Brien L, McDermott F, et al. A novel research design can aid disinvestment from existing health technologies with uncertain effectiveness, cost-effectiveness, and/or safety. J Clin Epidemiol. 2014;67:144-151.1
36. Moynihan RN. A healthy dose of disinvestment. Med J Aust. 2012;196:158.
37. Watt AM, Hiller JE, Braunack-Mayer AJ, et al. The ASTUTE health study protocol: Deliberative stakeholder engagements to inform im-plementation approaches to healthcare disinvestment. Implement Sci. 2012;7:101.
38. Ibargoyen-Roteta N, Gutierrez-Ibarluzea I, Asua J. Report on the development of the GuNFT guideline. Guideline for not funding existing health technologies in health care systems. 2007. http://www9.euskadi.net/sanidad/osteba/datos/e-10-11-report-GuNFT.pdf (accessed January 31, 2016).
39. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: The role of iterative decision analytic modelling. 2000. https://www.york.ac.uk/che/pdf/DP179.pdf (accessed January 31, 2016).
40. Hollingworth W, Chamberlain C. NICE recommendations for disinvestment. BMJ. 2011;343:d5772.
41. Jaurlaritza IE. HTAI summit examines disinvestment and the most cost-effective ways to manage current health technology. 2012. http://www.irekia.euskadi.eus/en/news/11317-htai-summit-examinesdisinvestment-and-the-most-cost-effective-ways-manage-currenthealth-technology (accessed January 16, 2016).
42. Scottish Health Technologies Group. Making choices spending wisely (MaCSWise) A report of current practice in NHSScotland relating to National Institute of Health and Clinical Excellence cost-saving recommendations. 2012. http://www.healthcareimprovementscotland.org/our-work/technologies-and-medicines/shtg-ad-hoc/macswise-report.aspx (accessed February 6, 2016).
43. Watt AM, Willis CD, Hodgetts K, Elshaug AG, Hiller JE. Engaging clinicians in evidence-based disinvestment: Role and perceptions of evidence. Int J Technol Assess Health Care. 2012;28:211-219.
44. Mayer J, Nachtnebel A. Identification of ineffective interventions and technologies: Existing models and their implementation. 2013. http://eprints.hta.lbg.ac.at/1014/(accessed February 7, 2016).
45. O'Callaghan G, Meyer H, Elshaug AG. Choosing wisely: The message, messenger and method. Med J Aust. 2015;202:175-177.